We're very sorry

Wir sind sehr traurig
Nous sommes très désolés
Siamo molto spiacenti
Estamos muy apesadumbrados
우리는 아주 유감스럽다
Мы очень огорченны
Nós somos muito pesarosos

The page you requested cannot be found

C1-Inhibitor Therapy
United States
Include All CSL Behring Country Sites

C1-Inhibitor Therapy

Hereditary angioedema (HAE) is a rare inherited disease that can cause considerable swelling in specific parts of the body, including the abdomen, face, and throat. People living with HAE types I and II have either low levels or dysfunctional blood protein called C 1 esterase inhibitor. When the production of C1 esterases goes unchecked, inflammation or leakage of fluid in the blood vessels (HAE attack) can occur.

There are three main types of HAE:
  • Type I: Levels of C1-INH are low in type I HAE. About 85% of people with HAE have type I, making it the most common type. It is equally likely to occur in men and women.
  • Type II: In type II HAE, the C1-INH levels are normal, but the existing C1-INH does not function properly. About 15% of people with HAE have type II, making it the second most common type of HAE. It is also equally likely to occur in men and women.
  • HAE with normal C1-INH: In HAE with normal C1-INH, lab tests are normal, but the person has symptoms of HAE. This type of HAE is an extremely rare type, and is not entirely understood. HAE with normal C1-INH occurs more often in women.

For more information please see these CSL Behring websites:


Important Safety Information for BERINERT

BERINERT®, C1 Esterase Inhibitor (Human), is used in adults and children to treat swelling and/or painful attacks of hereditary angioedema (HAE) affecting the abdomen, face or throat. The safety and efficacy of BERINERT in preventing HAE attacks have not been established.

Do not use BERINERT if you have experienced life-threatening allergic reactions or severe hypersensitivity to the product. Inform your healthcare provider of all medications you are taking and of any medical conditions, especially any history of blood-clotting problems.

Blood clots have occurred in patients receiving BERINERT. Tell your healthcare provider if you have a history of heart or blood vessel disease, stroke, or blood clots, or if you have thick blood, an indwelling catheter/access device in a vein, or have been immobile for some time. Certain medications, such as birth control pills, may also increase your risk of clotting problems.

Report to your physician or an emergency room any signs and symptoms of a blood clot, including pain and/or swelling or discoloration of an arm or leg, with warmth over affected area; unexplained shortness of breath; chest pain or discomfort that worsens on deep breathing; rapid pulse; and numbness or weakness on one side of the body.

In addition, report immediately any signs or symptoms of allergic reactions to BERINERT, including hives, chest tightness, wheezing, difficulty breathing, turning blue, faintness, facial swelling and fast heartbeat.

If you have been trained to self-administer BERINERT, immediately prepare the prescribed dose at the first symptoms of an attack. Seek immediate medical attention and do not begin to self-adminster if an HAE attack has progressed to a point where you will be unable to prepare or administer a dose of BERINERT.

If you self-administer to treat a laryngeal attack, immediately seek medical attention afterward. If you self-administer for an abdominal attack, inform your physician so that other possible causes can be ruled out.

Call your doctor right away if swelling is not controlled after use of BERINERT.

In clinical studies, the most serious adverse reaction reported in subjects who received BERINERT was an increased severity of the pain associated with HAE. In the placebo-controlled clinical trial, the most common adverse reaction reported more often among subjects who received BERINERT than those receiving placebo was dysgeusia (a bad taste in mouth). Tell your healthcare provider about any side effect that bothers you or does not go away.

Because BERINERT is made from human blood, the risk that it may transmit infectious agents, including viruses and theoretically, the agents of Creutzfeldt-Jakob Disease (CJD) and its variant form (vCJD), cannot be completely eliminated.

Please see full prescribing information for BERINERT, including the patient product information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

CRP16-05-0001 05/2016
© 2017 CSL Behring